OS Therapies Inc. Files 8-K with Corporate Updates

TL;DR

OS Therapies filed an 8-K on 8/15/25 for corporate updates and financials.

AI Summary

OS Therapies Inc. filed an 8-K on August 15, 2025, reporting amendments to its Articles of Incorporation or Bylaws and filing financial statements and exhibits. The company, incorporated in Delaware, is based in Grasonville, Maryland, with its principal executive offices at 115 Pullman Crossing Road, Suite 103.

Why It Matters

This filing indicates corporate housekeeping and the submission of financial documents, which are standard procedures for public companies to maintain transparency and regulatory compliance.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain any significant new risks or material adverse information.

Key Players & Entities

• OS Therapies Inc. (company) — Registrant
• August 15, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Grasonville, Maryland (location) — Principal Executive Offices Location
• 115 Pullman Crossing Road, Suite 103 (address) — Principal Executive Offices Address

FAQ

Key Financial Figures

• $0.001 — ch Registered Common Stock, par value $0.001 per share OSTX NYSE American Indi

Filing Documents

• ea0253338-8k_ostherap.htm (8-K) — 28KB
• ea025333801ex3-1_ostherap.htm (EX-3.1) — 4KB
• 0001213900-25-077431.txt ( ) — 200KB
• ostx-20250815.xsd (EX-101.SCH) — 3KB
• ostx-20250815_lab.xml (EX-101.LAB) — 33KB
• ostx-20250815_pre.xml (EX-101.PRE) — 22KB
• ea0253338-8k_ostherap_htm.xml (XML) — 4KB

03. Amendments to Articles of Incorporation

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On August 15, 2025, the Board of Directors (the "Board") of OS Therapies Incorporated (the "Company") approved and adopted an amendment (the "Amendment") to Section 3.10 of Article III of the Company's Amended and Restated Bylaws (the "Bylaws"), effective as of such date, to change the quorum for the transaction of business at stockholder meetings to one-third of the voting power of the outstanding shares of stock of the Company entitled to vote on a matter at the meeting, present in person or represented by proxy. For purposes of the foregoing, where a separate vote by class or classes is required for any matter, the holders of one-third of the voting power of the outstanding shares of such class or classes, present in person or represented by proxy, shall constitute a quorum to take action with respect to that vote on that matter. Except as specifically amended above, the Bylaws remain in full force and effect. The foregoing description of the Amendment is qualified in its entirety by reference to the full text of Amendment No. 1 to the Amended and Restated Bylaws of the Company, which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated by reference herein.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 3.1 Amendment No. 1 to the Amended and Restated Bylaws of OS Therapies Incorporated. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OS THERAPIES INCORPORATED Dated: August 15, 2025 By: /s/ Paul A. Romness, MPH Name: Paul A. Romness, MPH Title: President and Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR